- Home
- DYNX vs ANNX Comparison
DYNX vs ANNX Comparison
Compare DYNX & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYNX
- ANNX
- Stock Information
- Founded
- DYNX 2024
- ANNX 2011
- Country
- DYNX United States
- ANNX United States
- Employees
- DYNX N/A
- ANNX N/A
- Industry
- DYNX
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- DYNX
- ANNX Health Care
- Exchange
- DYNX NYSE
- ANNX Nasdaq
- Market Cap
- DYNX 221.3M
- ANNX 252.3M
- IPO Year
- DYNX 2024
- ANNX 2020
- Fundamental
- Price
- DYNX $10.19
- ANNX $2.38
- Analyst Decision
- DYNX
- ANNX Strong Buy
- Analyst Count
- DYNX 0
- ANNX 4
- Target Price
- DYNX N/A
- ANNX $12.50
- AVG Volume (30 Days)
- DYNX 15.7K
- ANNX 1.4M
- Earning Date
- DYNX 01-01-0001
- ANNX 08-11-2025
- Dividend Yield
- DYNX N/A
- ANNX N/A
- EPS Growth
- DYNX N/A
- ANNX N/A
- EPS
- DYNX N/A
- ANNX N/A
- Revenue
- DYNX N/A
- ANNX N/A
- Revenue This Year
- DYNX N/A
- ANNX N/A
- Revenue Next Year
- DYNX N/A
- ANNX N/A
- P/E Ratio
- DYNX N/A
- ANNX N/A
- Revenue Growth
- DYNX N/A
- ANNX N/A
- 52 Week Low
- DYNX $9.78
- ANNX $1.29
- 52 Week High
- DYNX $10.48
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- DYNX N/A
- ANNX 54.28
- Support Level
- DYNX N/A
- ANNX $2.26
- Resistance Level
- DYNX N/A
- ANNX $2.81
- Average True Range (ATR)
- DYNX 0.00
- ANNX 0.21
- MACD
- DYNX 0.00
- ANNX -0.02
- Stochastic Oscillator
- DYNX 0.00
- ANNX 45.68
About DYNX DYNAMIX CORP
Dynamix Corp is a blank check company.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.